Abstract:IMPORTANCE Improving the efficiency of interim assessments in phase III trials should reduce trial costs, hasten the approval of efficacious therapies, and mitigate patient exposure to disadvantageous randomizations. OBJECTIVE We hypothesized that in silico Bayesian early stopping rules improve the efficiency of phase III trials compared with the original frequentist analysis without compromising overall interpretation. DESIGN Cross-sectional analysis. SETTING 230 randomized phase III oncology trials enrolling 184,752 participants. PARTICIPANTS Individual patient-level data were manually reconstructed from primary endpoint Kaplan-Meier curves. INTERVENTIONS Trial accruals were simulated 100 times per trial and leveraged published patient outcomes such that only the accrual dynamics, and not the patient outcomes, were randomly varied. MAIN OUTCOMES AND MEASURES Early stopping was triggered per simulation if interim analysis demonstrated >= 85% probability of minimum clinically important difference/3 for efficacy or futility. Trial-level early closure was defined by stopping frequencies >= 0.75. RESULTS A total of 12,451 simulations (54%) met early stopping criteria. Trial-level early stopping frequency was highly predictive of the published outcome (OR, 7.24; posterior probability of association, >99.99%; AUC, 0.91; P < 0.0001). Trial-level early closure was recommended for 82 trials (36%), including 62 trials (76%) which had performed frequentist interim analysis. Bayesian early stopping rules were 96% sensitive (95% CI, 91% to 98%) for detecting trials with a primary endpoint difference, and there was a high level of agreement in overall trial interpretation (Bayesian Cohen k, 0.95; 95% CrI, 0.92 to 0.99). However, Bayesian interim analysis was associated with >99.99% posterior probability of reducing patient enrollment requirements (P < 0.0001), with an estimated cumulative enrollment reduction of 20,543 patients (11%; 89 patients averaged equally over all studied trials) and an estimated cumulative cost savings of 851 million USD (3.7 million USD averaged equally over all studied trials). CONCLUSIONS AND RELEVANCE Bayesian interim analyses may improve randomized trial efficiency by reducing enrollment requirements without compromising trial interpretation. Increased utilization of Bayesian interim analysis has the potential to reduce costs of late-phase trials, reduce patient exposures to ineffective therapies, and accelerate approvals of effective therapies.

Patient-Centered Clinical Trial Design for Heart Failure Devices via Bayesian Decision Analysis

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

The "small" clinical trial: Methods, analysis and interpretation in acute care cardiology.

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Adaptive Clinical Trials in Stroke

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

The performance of a Bayesian value-based sequential clinical trial design in the presence of an equivocal cost-effectiveness signal: evidence from the HERO trial

Developing an Individualized Patient Decision Aid for Chronic Coronary Disease Based on the ISCHEMIA Trial: A Mixed-Methods Study

Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials

Beyond p-values: a phase II dual-criterion design with statistical significance and clinical relevance

A general Bayesian approach to design adaptive clinical trials with time-to-event outcomes

Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium

Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials

Decision-making with multiple correlated binary outcomes in clinical trials

Qualitative Analysis of Patient Decisional Needs for Medications to Treat Heart Failure

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials

Utilizing Quality of Life Adjusted Days Alive and Out of Hospital in Heart Failure Clinical Trials